Willow

Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™

Retrieved on: 
Wednesday, April 3, 2024
Infectious Diseases, Biotechnology, Pharmaceutical, Health, Molluscum contagiosum, LGND, Medication, Caregiver, Partnership, Willow, Patient, Salix Pharmaceuticals, Senior, Ligand Pharmaceuticals, Therapy, Multimedia, Parent, Food, Pharmaceutical industry

Ligand Pharmaceuticals (Nasdaq: LGND) today announced the launch of Pelthos Therapeutics (Pelthos), a biopharmaceutical company, and the appointment of seasoned industry executive Scott Plesha to the role of Chief Executive Officer.

Key Points: 
  • Ligand Pharmaceuticals (Nasdaq: LGND) today announced the launch of Pelthos Therapeutics (Pelthos), a biopharmaceutical company, and the appointment of seasoned industry executive Scott Plesha to the role of Chief Executive Officer.
  • Ligand acquired the rights to ZELSUVMI and all the assets related to the NITRICIL technology platform from Novan, Inc. in September 2023.
  • To date, Ligand has created three companies utilizing this strategy: Viking Therapeutics, Primrose Bio, and OmniAb®.
  • Pelthos is a wholly owned subsidiary of Ligand.

WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIALS AND OPERATIONS AND FILING OF ITS 2023 AIF

Retrieved on: 
Thursday, March 28, 2024
Partnership, HTP, Prednisolone, Enzyme, DNA, Hydrocortisone, Budesonide, Willow, Fine chemical

Transition of R&D programs to commercial revenue: With multiple R&D programs now complete or nearing completion, the Company anticipates generating first commercial revenues from at least two products as they transition to commercial production.

Key Points: 
  • Transition of R&D programs to commercial revenue: With multiple R&D programs now complete or nearing completion, the Company anticipates generating first commercial revenues from at least two products as they transition to commercial production.
  • Commercial revenue is expected to be potentially milestone, royalty, and ingredient supply revenue.
  • Significant increase in revenues: Full year R&D revenues for 2024 are expected to increase by over 100% compared to 2023.
  • In addition, commercial stage revenue is expected to commence on multiple programs.

WILLOW BIOSCIENCES ANNOUNCES SECOND STRATEGIC INVESTMENT FROM KALSEC

Retrieved on: 
Thursday, February 29, 2024
AB, WLLW, TSX, Toronto Stock Exchange, Warrant, Food, Indian stock exchange, Willow, Acceleration, Legislation, Security (finance)

CALGARY, AB, Feb. 29, 2024 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, is pleased to announce a second strategic investment (the "Milestone Investment"), by way of non-brokered private placement, from Kalsec® Inc. ("Kalsec"), a leading global producer of natural taste and sensory, food protection, colors and advanced hops ingredients for the food and beverage industry, for the continued development of natural food ingredients.

Key Points: 
  • CALGARY, AB, Feb. 29, 2024 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent, and sustainable functional ingredients, is pleased to announce a second strategic investment (the "Milestone Investment"), by way of non-brokered private placement, from Kalsec® Inc. ("Kalsec"), a leading global producer of natural taste and sensory, food protection, colors and advanced hops ingredients for the food and beverage industry, for the continued development of natural food ingredients.
  • This Milestone Investment is connected to the Kalsec investment announced by the Company on February 20, 2024, pursuant to which Kalsec committed to subscribe for an additional US$100,000.00 on the completion of an operational milestone by Willow to develop a strain that meets certain performance criteria (the "Milestone").
  • Proceeds from the Milestone Investment will be used for the commercialization and development of the Company's pipeline of products, including natural food ingredients, working capital, and general corporate purposes.
  • All securities issued under the Milestone Investment, including securities issuable on exercise thereof, are subject to a hold period in Canada of four months and one day in accordance with applicable securities legislation.

Proven Behavior Solutions Appoints Mark Donovan to Board of Directors

Retrieved on: 
Friday, February 2, 2024
ASD, Senior, Autism spectrum, Strategic planning, Occupational therapy, ABA, Partner, Willow, Applied behavior analysis, Business, Health, Nursing

NORWELL, Mass., Feb. 2, 2024 /PRNewswire/ -- Proven Behavior Solutions ("Proven"), a leading provider of clinical services to children and adolescents diagnosed with Autism Spectrum Disorder (ASD) in Southeast Massachusetts, announced today that it has appointed a new independent director, Mark Donovan , to its Board of Directors.

Key Points: 
  • NORWELL, Mass., Feb. 2, 2024 /PRNewswire/ -- Proven Behavior Solutions ("Proven"), a leading provider of clinical services to children and adolescents diagnosed with Autism Spectrum Disorder (ASD) in Southeast Massachusetts, announced today that it has appointed a new independent director, Mark Donovan , to its Board of Directors.
  • Leading Northeast autism services provider, Proven Behavior Solutions, announces new Board member.
  • Donovan most recently served as the Chief Executive Officer of Attain ABA, a multi-state provider of ABA therapy services.
  • Proven provides both clinic-based and in-home Applied Behavior Analysis (ABA) therapy, speech-language therapy, occupational therapy, and special education advocacy services.

WILLOW ANNOUNCES COLLABORATION WITH GLOBAL INGREDIENT MANUFACTURER TO DEVELOP A MORE COST-EFFECTIVE, SUSTAINABLE PROCESS FOR A LARGE VOLUME ACTIVE PHARMACEUTICAL INGREDIENT

Retrieved on: 
Wednesday, January 31, 2024
Partnership, Active ingredient, TSX, Health, API, WLLW, Willow, Fine chemical

The new partnership program will focus on optimization of an existing commercial biomanufacturing process for improved performance at scale.

Key Points: 
  • The new partnership program will focus on optimization of an existing commercial biomanufacturing process for improved performance at scale.
  • The development phase of this funded collaboration is expected to last approximately six months with additional milestone payments to be made for achieving defined performance targets.
  • "We are excited to once again apply our technology platform to the manufacture of more sustainable APIs for existing, large volume global markets," said Dr. Chris Savile, Willow's President & CEO.
  • This agreement represents the second new development agreement executed by Willow in only the first few weeks of 2024, with a robust pipeline of other potential collaborations in process.

LeapCharger Set to Enter Canadian Market, Inks Agreement with Willow Manor Creek for Installation of EV Chargers

Retrieved on: 
Wednesday, December 13, 2023
Willow, LCCN, Partnership, Swift Current, Strategic partnership, Growth, Organization, OTC, EV

Willow Manor Creek Long-Term Care Facility, renowned for its dedication to environmental stewardship, aligns seamlessly with LeapCharger's mission to create a cleaner and more energy-efficient future.

Key Points: 
  • Willow Manor Creek Long-Term Care Facility, renowned for its dedication to environmental stewardship, aligns seamlessly with LeapCharger's mission to create a cleaner and more energy-efficient future.
  • The Partnership will focus on the installation of multiple cutting-edge EV charging stations at Willow Manor Creek during the first quarter of 2024, providing residents, visitors, and the local community with convenient access to sustainable energy solutions.
  • “LeapCharger's entry into the Canadian market is poised to have a profoundly positive impact on the Company's long-term growth.
  • LeapCharger Corporation and Willow Manor Creek Long-Term Care Facility invite shareholders and stakeholders to celebrate this momentous partnership.

CA Ventures Announces $65 Million Sale of Fort Collins Apartment Building, 281 Willow

Retrieved on: 
Wednesday, November 15, 2023
Residential Building & Real Estate, Construction & Property, REIT, Sale, Walker, CSU, Multimedia, Walker & Dunlop, Faculty, Colorado State University, Willow, Restaurant, Property management, Financial services

CA Ventures , an international real estate investment, development and management company, is excited to announce the sale of 281 Willow, an apartment building ideally located in Fort Collins, Colorado.

Key Points: 
  • CA Ventures , an international real estate investment, development and management company, is excited to announce the sale of 281 Willow, an apartment building ideally located in Fort Collins, Colorado.
  • View the full release here: https://www.businesswire.com/news/home/20231114275042/en/
    CA Ventures recently sold 281 Willow to Borello Asset Management Inc. (Photo: Business Wire)
    The $65 million sale, which closed on September 28, was made possible due to the leadership of CA Ventures CEO Tom Scott and Chief Investment Officer John Diedrich .
  • The sale was arranged by the Walker & Dunlop Denver Investment Sales team on behalf of CA Ventures, the client, and Borello Asset Management Inc., which was the buyer.
  • 281 Willow is a 197-unit, newly constructed Class A apartment community conveniently located in the flourishing market of Fort Collins, Colorado, which has strong multifamily fundamentals.

WILLOW AND LEADING INNOVATIVE BIOPHARMACEUTICAL COMPANY ADVANCE DEVELOPMENT PROGRAM TO MANUFACTURE SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS

Retrieved on: 
Thursday, December 7, 2023
R, Willow, WLLW, API, TSX, Willow Garage, Fine chemical

SUNNYVALE, Calif., Dec. 7, 2023 /PRNewswire/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, and a Nasdaq-listed biopharma company are advancing their program to develop precise, concise manufacturing routes to advanced intermediates and high-value active pharmaceutical ingredients.

Key Points: 
  • SUNNYVALE, Calif., Dec. 7, 2023 /PRNewswire/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, and a Nasdaq-listed biopharma company are advancing their program to develop precise, concise manufacturing routes to advanced intermediates and high-value active pharmaceutical ingredients.
  • The parties' phase one feasibility program that applied Willow's BioOxi™ platform exceeded expectations and the partner has now agreed to continue full development toward commercialization, including additional R&D and scale-up work.
  • "We appreciate the trust our partner has in Willow to develop sustainable manufacturing routes to APIs and are delighted to continue to work with them to further develop and supply key advanced intermediates to support their development pipeline," said Dr. Chris Savile, Willow's President & CEO.
  • "This is truly an exciting time for Willow and the BioOxi platform as we rapidly move from R&D to manufacturing and supply in 2024."

Project Sweet Peas and Willow Innovations Team Up To Support NICU Parents for Giving Tuesday

Retrieved on: 
Monday, November 20, 2023
Sale, Nicu Ceaușescu, SAN, NICU, Entrepreneurship, Partnership, Freedom, Parent, Volunteering, Suction, Toy, Willow, R.I, Femtech

WARWICK, R.I. and SAN FRANCISCO, Nov. 20, 2023 /PRNewswire/ -- Today, Project Sweet Peas, a national nonprofit organization that supports neonatal intensive care units (NICUs) families of fragile infants, and Willow Innovations, Inc. (Willow), the Femtech leader disrupting the pumping and feeding industry, announced their partnership to support NICU families this holiday. Project Sweet Peas and Willow are joining forces during Giving Tuesday to donate care packages to support the bonding and feeding process between parents and babies in NICUs.

Key Points: 
  • Project Sweet Peas and Willow are joining forces during Giving Tuesday to donate care packages to support the bonding and feeding process between parents and babies in NICUs.
  • When anyone makes a Willow pump purchase at onewillow.com on Tuesday, November 28, Willow will donate a portion of the purchase sale to Project Sweet Peas to provide packages of carefully selected items designed for both parents and baby and award-winning Willow Go breast pumps to NICU parents*.
  • Project Sweet Peas will create a program to distribute care packages and Willow Go breast pumps to NICU parents.
  • Project Sweet Peas is coordinated by volunteers, who are former NICU parents and passionate about providing support to families of premature or sick infants.

WILLOW BIOSCIENCES REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Retrieved on: 
Tuesday, November 14, 2023
UDCA, Research, Commercial, Bank statement, WLLW, Willow Garage, Steroid, API, Partnership, Ursodeoxycholic acid, R, TSX, Patent, Pharmaceutical industry, Fine chemical, Renewable energy, Video game, Willow, Q4

On July 20, 2023, Willow announced our savory food program with Kalsec Inc. progressed past the feasibility stage and into the R&D and scale-up work stage.

Key Points: 
  • On July 20, 2023, Willow announced our savory food program with Kalsec Inc. progressed past the feasibility stage and into the R&D and scale-up work stage.
  • On October 24, 2023, Aurora Cannabis Inc. and Willow announced a confidential settlement resolving the ongoing patent ligation in Canada.
  • Willow ended the quarter with approximately $4.0 million in cash as of September 30, 2023, plus receivables of over $0.6 million.
  • On September 12, 2023, Willow announced an insider led convertible debenture financing, which was closed on October 10, 2023 for gross proceeds of $0.8 million.